Literature DB >> 16385585

Behavioral motor recovery in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned squirrel monkey (Saimiri sciureus): changes in striatal dopamine and expression of tyrosine hydroxylase and dopamine transporter proteins.

Giselle M Petzinger1, Beth Fisher, Elizabeth Hogg, Avery Abernathy, Pablo Arevalo, Kerry Nixon, Michael W Jakowec.   

Abstract

The neurotoxicant 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) provides an excellent opportunity to study repair and response to injury in the basal ganglia. Administration to mammals leads to the destruction of nigrostriatal dopaminergic neurons and depletion of striatal dopamine. In the squirrel monkey (Saimiri sciureus), MPTP-lesioning results in parkinsonian motor symptoms including bradykinesia, postural instability, and rigidity. Over time animals display motor behavioral recovery. To better understand this mechanism we employed a lesioning regimen of two or six subcutaneous injections of MPTP (2.0 mg/kg, free-base) to generate mild or moderate parkinsonism. Brain tissue was harvested at 6 weeks or 9 months after the last injection and analyzed for dopamine and its metabolites by high performance liquid chromatography (HPLC), and by immunohistochemical staining and Western immunoblotting for the expression of tyrosine hydroxylase (TH), dopamine transporter (DAT), and dopamine- and cAMP-responsive protein phosphatase of 32 kDa (DARPP-32), an effector molecule enriched in striatal medium spiny neurons. Several months after MPTP-lesioning, when squirrel monkeys displayed full motor behavioral recovery, striatal dopamine levels remained low with a greater return in the ventral striatum. This finding is consistent with other reports using neurotoxicant-lesioning models of the basal ganglia in rodents and other species of nonhuman primates. Elevated dopamine turnover ratio and decreased DAT expression appeared in early behavioral recovery at the 6-week time point in both mild- and moderate-parkinsonian monkeys. Tyrosine hydroxylase and DAT expression was increased in late stage recovery even within dopamine-depleted regions and supports sprouting. Altered DARPP-32 expression suggests a role of medium spiny neurons in recovery. Copyright 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16385585     DOI: 10.1002/jnr.20730

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  12 in total

1.  Effects of neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treatment on ovarian development of the sapphire devil, Chrysiptera cyanea.

Authors:  Muhammad Badruzzaman; Satoshi Imamura; Yuki Takeuchi; Taro Ikegami; Akihiro Takemura
Journal:  Fish Physiol Biochem       Date:  2014-11-02       Impact factor: 2.794

2.  Reactive astrocytes and Wnt/β-catenin signaling link nigrostriatal injury to repair in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.

Authors:  F L'Episcopo; C Tirolo; N Testa; S Caniglia; M C Morale; C Cossetti; P D'Adamo; E Zardini; L Andreoni; A E C Ihekwaba; P A Serra; D Franciotta; G Martino; S Pluchino; B Marchetti
Journal:  Neurobiol Dis       Date:  2010-11-05       Impact factor: 5.996

3.  Behavioral phenotypes associated with MPTP induction of partial lesions in common marmosets (Callithrix jacchus).

Authors:  Kimberley A Phillips; Corinna N Ross; Jennifer Spross; Catherine J Cheng; Alyssa Izquierdo; K C Biju; Cang Chen; Senlin Li; Suzette D Tardif
Journal:  Behav Brain Res       Date:  2017-02-17       Impact factor: 3.332

4.  Inhibition of DAT function attenuates manganese accumulation in the globus pallidus.

Authors:  Joel G Anderson; Paula T Cooney; Keith M Erikson
Journal:  Environ Toxicol Pharmacol       Date:  2007-03       Impact factor: 4.860

5.  Memory, mood, dopamine, and serotonin in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse model of basal ganglia injury.

Authors:  Marta G Vucković; Ruth I Wood; Daniel P Holschneider; Avery Abernathy; Daniel M Togasaki; Alexandra Smith; Giselle M Petzinger; Michael W Jakowec
Journal:  Neurobiol Dis       Date:  2008-08-05       Impact factor: 5.996

6.  Effects of treadmill exercise on dopaminergic transmission in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse model of basal ganglia injury.

Authors:  Giselle M Petzinger; John P Walsh; Garnik Akopian; Elizabeth Hogg; Avery Abernathy; Pablo Arevalo; Patty Turnquist; Marta Vucković; Beth E Fisher; Daniel M Togasaki; Michael W Jakowec
Journal:  J Neurosci       Date:  2007-05-16       Impact factor: 6.167

7.  Early presymptomatic and long-term changes of rest activity cycles and cognitive behavior in a MPTP-monkey model of Parkinson's disease.

Authors:  Julien Vezoli; Karim Fifel; Vincent Leviel; Colette Dehay; Henry Kennedy; Howard M Cooper; Claude Gronfier; Emmanuel Procyk
Journal:  PLoS One       Date:  2011-08-24       Impact factor: 3.240

Review 8.  An adverse outcome pathway for parkinsonian motor deficits associated with mitochondrial complex I inhibition.

Authors:  Andrea Terron; Anna Bal-Price; Alicia Paini; Florianne Monnet-Tschudi; Susanne Hougaard Bennekou; Marcel Leist; Stefan Schildknecht
Journal:  Arch Toxicol       Date:  2017-12-05       Impact factor: 5.153

Review 9.  Adult Endogenous Dopaminergic Neuroregeneration Against Parkinson's Disease: Ideal Animal Models?

Authors:  Yuganthini Vijayanathan; Siong Meng Lim; Maw Pin Tan; Fei Ting Lim; Abu Bakar Abdul Majeed; Kalavathy Ramasamy
Journal:  Neurotox Res       Date:  2020-11-03       Impact factor: 3.911

Review 10.  Exercise-Induced Neuroprotection of the Nigrostriatal Dopamine System in Parkinson's Disease.

Authors:  Lijuan Hou; Wei Chen; Xiaoli Liu; Decai Qiao; Fu-Ming Zhou
Journal:  Front Aging Neurosci       Date:  2017-11-03       Impact factor: 5.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.